基本信息:
- 专利标题： 점안제
- 专利标题（英）：KR101838759B1 - Eye drops
- 专利标题（中）：眼药水
- 申请号：KR1020127009088 申请日：2010-09-24
- 公开(公告)号：KR101838759B1 公开(公告)日：2018-03-14
- 发明人： 나카무라다카히로 , 나카다유이치로 , 나가노다카시 , 나카무라마사츠구
- 申请人： 가부시키가이샤 아루떼꾸 우에노
- 申请人地址： *-*, Uchisaiwai-cho *-chome, Chiyoda-ku, Tokyo, ******* Japan
- 专利权人： 가부시키가이샤 아루떼꾸 우에노
- 当前专利权人： 가부시키가이샤 아루떼꾸 우에노
- 当前专利权人地址： *-*, Uchisaiwai-cho *-chome, Chiyoda-ku, Tokyo, ******* Japan
- 代理人： 김태홍; 김진회
- 优先权： JPJP-P-2009-220235 2009-09-25
- 国际申请： PCT/JP2010/066488 2010-09-24
- 国际公布： WO2011037157 2011-03-31
- 主分类号： A61K38/07
- IPC分类号： A61K38/07 ; A61K38/30 ; A61K9/00 ; C07K5/103 ; C07K5/107 ; A61K47/02 ; A61K9/08
The present invention, the amino acid sequence Ser-Ser-Ser-Arg peptide represented by (SSSR), or acceptable salts a pharmaceutically and amino acid sequence of the peptide (FGLM) represented by Phe-Gly-Leu-Met- NH 2 or to maximize the efficacy of eye drops containing a pharmaceutically acceptable salts and minimize the occurrence of side effects, and a problem of improving the storage stability of the eye drops.
The concentration ratio of the formulation acceptable salts and salts FGLM or a pharmaceutically acceptable, or a pharmaceutically SSSR as a 1 / 15-1 / 50, and 0.001~0.3% of the combined concentration of the SSSR or a pharmaceutically acceptable salts (w / v) by a, and the combined concentration of the FGLM or a pharmaceutically acceptable salts in 0.015~1.5% (w / v), and also maintain a pH range of 2.5 to 6.5 as eye drops, it is possible to achieve the foregoing object.
公开/授权文献:
- KR1020120088700A 점안제 公开/授权日：2012-08-08
信息查询:
EspacenetIPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K38/00 | 含肽的医药配制品 |
| --------A61K38/04 | .在完全确定的序列中最多有20个氨基酸的肽；其衍生物 |
| ----------A61K38/07 | ..四肽 |